Cite
Ofatumumab with iphosphamide, etoposide and cytarabine for patients with transplantation-ineligible relapsed and refractory diffuse large B-cell lymphoma.
MLA
Paszkiewicz-Kozik, Ewa, et al. “Ofatumumab with Iphosphamide, Etoposide and Cytarabine for Patients with Transplantation-Ineligible Relapsed and Refractory Diffuse Large B-Cell Lymphoma.” British Journal of Haematology, vol. 198, no. 1, July 2022, pp. 73–81. EBSCOhost, https://doi.org/10.1111/bjh.18166.
APA
Paszkiewicz-Kozik, E., Michalski, W., Taszner, M., Mordak-Domagała, M., Romejko-Jarosińska, J., Knopińska-Posłuszny, W., Najda, J., Borawska, A., Chełstowska, M., Świerkowska, M., Dąbrowska-Iwanicka, A., Malenda, A., Druzd-Sitek, A., Konecki, R., Kumiega, B., Osowiecki, M., Ostrowska, B., Szpila, T., Szymański, M., … Walewski, J. (2022). Ofatumumab with iphosphamide, etoposide and cytarabine for patients with transplantation-ineligible relapsed and refractory diffuse large B-cell lymphoma. British Journal of Haematology, 198(1), 73–81. https://doi.org/10.1111/bjh.18166
Chicago
Paszkiewicz-Kozik, Ewa, Wojciech Michalski, Michał Taszner, Monika Mordak-Domagała, Joanna Romejko-Jarosińska, Wanda Knopińska-Posłuszny, Jacek Najda, et al. 2022. “Ofatumumab with Iphosphamide, Etoposide and Cytarabine for Patients with Transplantation-Ineligible Relapsed and Refractory Diffuse Large B-Cell Lymphoma.” British Journal of Haematology 198 (1): 73–81. doi:10.1111/bjh.18166.